who discovered glp-1 agonists Dual GLP-1/GIP receptor agonists mechanism

[DOI] [PMC free article] [PubMed] [Google Scholar] 117.Sukumaran V., Tsuchimochi H., Sonobe T., Waddingham M.T., Shirai M., Pearson J.T

Christensen, M., Knop, F

WEDNESDAY, July 23, 2025 (HealthDay News) -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with metformin, according to a study published online July 22 in BMJ Open Diabetes Research & Care.Mingyang Sun, from the People's Hospital of Zhengzhou University in China, and colleagues conducted a retrospective cohort study using data from a global health research network between 2004 and 2024 to examine the comparative effectiveness of GLP-1 RAs and metformin in reducing dementia risk

Expanding Pipeline The GLP-1 pipeline is rich with new indications for existing FDA approved drugs as well as new market entrants

Although this type of medication is FDA-approved, that doesnt mean it is safe for everyone Side effects associated with GLP-1 agonists: Common side effects of GLP-1 agonists include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, dizziness, and fatigue

These combined metabolic effects generate that familiar feeling of fullness after a meal